Bayer Wants Full Fed. Circ. Scrutiny Of Axed Xarelto Claims
Bayer Pharma Aktiengesellschaft is urging the full Federal Circuit to scrutinize a decision that declined to revive claims in a patent covering its blockbuster blood thinner, saying Wednesday that a panel...To view the full article, register now.
Already a subscriber? Click here to view full article